Rapport Therapeutics Inc. [RAPP] stock prices are up 4.84% to $21.23 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RAPP shares have gain 11.74% over the last week, with a monthly amount drifted -5.52%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Stifel started tracking the stock with Buy rating on July 02, 2024, and set its price target to $35. On July 02, 2024, Jefferies initiated with a Buy rating and assigned a price target of $35 on the stock.
The stock price of Rapport Therapeutics Inc. [RAPP] has been fluctuating between $16.55 and $28.08 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Rapport Therapeutics Inc. [NASDAQ: RAPP] shares were valued at $21.23 at the most recent close of the market. An investor can expect a potential return of 64.86% based on the average RAPP price forecast.
Analyzing the RAPP fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.15 and Total Capital is -0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.68 points at the first support level, and at 18.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.22, and for the 2nd resistance point, it is at 23.21.
Ratios To Look Out For
It’s worth pointing out that Rapport Therapeutics Inc. [NASDAQ:RAPP]’s Current Ratio is 42.08. On the other hand, the Quick Ratio is 42.08, and the Cash Ratio is 13.62.
Transactions by insiders
Recent insider trading involved HEALY JAMES, Director, that happened on Jul 01 ’24 when 44032.0 shares were purchased. Director, HEALY JAMES completed a deal on Jun 10 ’24 to buy 0.56 million shares.
